Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone

/PRNewswire/ -- On the 24th of May, Kexing Biopharm (688136.SH) announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently...

Related Keywords

China ,Shenzhen ,Guangdong ,Kexing Biopharm ,National Medical Products Administration ,Shenzhen Kexing Pharmaceutical Co Ltd ,Drug Clinical Trials ,